Covidien Expands In GI Market With Given Imaging
Covidien (COV) stock edged up Monday after the company on Sunday announced its third acquisition in little more than two years that expands its presence in the market for treating gastrointestinal, or GI, ailments. Ireland-based Covidien said it would buy Israel-based Given Imaging (GIVN) for $860 million, or $30 a share. That’s 27% above Given’s closing price Friday, and the lightly traded Given stock was up more than 25%, near 29.75, in morning